David Scheinberg

David Scheinberg

Company: Memorial Sloan Kettering Cancer Center

Job title: Chairman, Molecular Pharmacology Program; & Experimental Therapeutics Center


Panel Discussion: Exploring the Potential of Soluble TCR Therapies to Redirect and Activate T Cells 1:00 pm

How do we enhance receptor-target interactions to develop safe and efficacious soluble TCR products? Beyond survival benefit, how do we define the clinical response rate to determine success in phase 3 clinical trials? What are the lessons that we have taken from antibodies?Read more

day: Day Two

TCR Mimics as a Platform for Soluble Therapeutic Agents 12:30 pm

Monoclonal antibodies can be constructed with specificities that mimic a TCR The advantages and disadvantages of such platforms are describedRead more

day: Day Two

Identifying The On And Off Targets Of TCR Based Agents 4:30 pm

TCR’s are highly promiscuous leading to potential toxicities Empirical methods to determine the potential targets of TCR-based agents are describedRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.